Theravance Biopharma Inc.

NASDAQ: TBPH · Real-Time Price · USD
9.51
0.10 (1.06%)
At close: May 22, 2025, 3:59 PM
9.49
-0.16%
After-hours: May 22, 2025, 04:04 PM EDT

Theravance Biopharma Statistics

Share Statistics

Theravance Biopharma has 50M shares outstanding. The number of shares has increased by 1.72% in one year.

Shares Outstanding 50M
Shares Change (YoY) 1.72%
Shares Change (QoQ) 0.6%
Owned by Institutions (%) 91.54%
Shares Floating n/a
Failed to Deliver (FTD) Shares 415
FTD / Avg. Volume 0.15%

Short Selling Information

The latest short interest is 3.89M, so 7.91% of the outstanding shares have been sold short.

Short Interest 3.89M
Short % of Shares Out 7.91%
Short % of Float 15.37%
Short Ratio (days to cover) 17.97

Valuation Ratios

The PE ratio is -8.15 and the forward PE ratio is -8.07. Theravance Biopharma's PEG ratio is -0.54.

PE Ratio -8.15
Forward PE -8.07
PS Ratio 7.14
Forward PS 1.9
PB Ratio 2.62
P/FCF Ratio -38.73
PEG Ratio -0.54
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Theravance Biopharma.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 5.02, with a Debt / Equity ratio of 0.28.

Current Ratio 5.02
Quick Ratio 5.02
Debt / Equity 0.28
Debt / EBITDA -1.06
Debt / FCF -4.2
Interest Coverage -18.44

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $663,721.65
Profits Per Employee $-581,628.87
Employee Count 97
Asset Turnover 0.18
Inventory Turnover n/a

Taxes

Income Tax 11.8M
Effective Tax Rate -26.46%

Stock Price Statistics

The stock price has increased by 4.57% in the last 52 weeks. The beta is -0.1, so Theravance Biopharma's price volatility has been lower than the market average.

Beta -0.1
52-Week Price Change 4.57%
50-Day Moving Average 9.22
200-Day Moving Average 8.98
Relative Strength Index (RSI) 51.44
Average Volume (20 Days) 274,413

Income Statement

In the last 12 months, Theravance Biopharma had revenue of 64.38M and earned -56.42M in profits. Earnings per share was -1.15.

Revenue 64.38M
Gross Profit 58.37M
Operating Income -46.95M
Net Income -56.42M
EBITDA -46.95M
EBIT -47.16M
Earnings Per Share (EPS) -1.15
Full Income Statement

Balance Sheet

The company has 37.8M in cash and 49.82M in debt, giving a net cash position of -12.02M.

Cash & Cash Equivalents 37.8M
Total Debt 49.82M
Net Cash -12.02M
Retained Earnings -965.52M
Total Assets 343.58M
Working Capital 118.76M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -11.54M and capital expenditures -332K, giving a free cash flow of -11.87M.

Operating Cash Flow -11.54M
Capital Expenditures -332K
Free Cash Flow -11.87M
FCF Per Share -0.24
Full Cash Flow Statement

Margins

Gross margin is 90.66%, with operating and profit margins of -72.92% and -87.63%.

Gross Margin 90.66%
Operating Margin -72.92%
Pretax Margin -69.3%
Profit Margin -87.63%
EBITDA Margin -72.92%
EBIT Margin -72.92%
FCF Margin -18.43%

Dividends & Yields

TBPH does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for TBPH is $10, which is 6.5% higher than the current price. The consensus rating is "Hold".

Price Target $10
Price Target Difference 6.5%
Analyst Consensus Hold
Analyst Count 3
Stock Forecasts

Scores

Altman Z-Score -2.32
Piotroski F-Score 4